OBJECTIVES The aim of this study was to evaluate the late clinical performance of a polymer-free sirolimus-and probucol-eluting stent compared with a new-generation durable polymer-based zotarolimus-eluting stent.
been previously reported (12) . In brief, between Patients who met all of the inclusion criteria and none of the exclusion criteria were randomized in the order in which they qualified. Patients were assigned to receive polymer-free sirolimusand probucol-eluting stents or permanent polymer zotarolimus-eluting stents in a 2:1 allocation. The polymer-free stent platform consists of a premounted, sand-blasted, 316L stainless steel microporous stent coated with a mixture of sirolimus, probucol, and shellac resin (a biocompatible resin widely used in the coating of medical tablets).
The permanent polymer zotarolimus-eluting stent (Resolute; Medtronic Cardiovascular, Santa Clara, California) consists of a thin-strut stainless steel stent platform (Driver). The polymer coating system (BioLinx) consists of 3 different polymers: a hydrophobic C10 polymer, a hydrophilic C19 polymer, and polyvinylpyrrolidinone. Further detailed descriptions of stent platforms and elution characteristics of both stents have been reported previously (7, 11, 13, 14) . The aim of the present study was to compare outcomes of patients treated with polymer-free sirolimusand probucol-eluting stents versus permanent polymer zotarolimus-eluting stents after 5-year clinical follow-up. For lesion-level data, differences between groups were checked for significance using generalized estimating equations for data not normally distributed to address intrapatient correlation in patients who underwent multiple-lesion intervention (15).
Event-free survival was assessed using the KaplanMeier method. Hazard ratios (HRs), confidence intervals (CIs), and p values were calculated from univariate Cox proportional hazards models. The proportional hazards assumption was checked by the method of Grambsch and Therneau (16) and was fulfilled in all cases in which we used Cox proportional hazards models. The analysis of primary and secondary endpoints was planned to be performed on an intention-to-treat basis (17) . Analysis of the primary outcome was also performed for pre-specified subsets of interest: old and young patients (above and at or below the median age), men and women, patients with and those without diabetes, and small and large vessels (below and at or above the median value).
Interaction between treatment effect and these covariates was assessed using Cox proportional hazards models. S-PLUS version 4.5 (Insightful Corporation, Seattle, Washington) was used for statistical analysis.
RESULTS

PATIENTS.
A total of 3,002 patients were enrolled and randomized to receive either polymer-free sirolimus-and probucol-eluting (n ¼ 2,002) or durable polymer zotarolimus-eluting (n ¼ 1000) stents.
As shown in Table 1 and possible stent thrombosis are displayed in Table 3 .
There was no evidence of an interaction between treatment effect and each of the pre-specified subgroups of age, sex, diabetes, and vessel size ( Figure 3 ).
PATIENT-ORIENTED OUTCOMES AT 5 YEARS.
Regarding the composite endpoint of death, any MI, or any revascularization, there was no difference be- 
DISCUSSION
The main findings of our study were that in a largescale randomized controlled trial, the primary composite outcome measure of cardiac death, target vessel-related MI, or target lesion revascularization occurred with equal frequency at 5 years in patients randomized to treatment with a polymerfree probucol-and sirolimus-eluting stent in comparison with a durable polymer zotarolimus-eluting stent. Moreover, durability of efficacy was high,
FIGURE 1 Time-to-Event Curves
Time-to-event curves for the incidence of (A) the primary composite endpoint of cardiac death, myocardial infarction related to the target vessel, or target lesion revascularization; (B) the composite of cardiac death or myocardial infarction related to the target vessel; and (C) target lesion revascularization. Hazard ratios (HRs) and p values are derived from Cox proportional hazard methods. CI ¼ confidence interval.
Kufner et al. Hazard ratios (HRs) and p values are derived from Cox proportional hazard methods. The results of our trial add to the number of reports of late follow-up from coronary stent trials with minimal exclusion criteria (23) (24) (25) (26) . In keeping with these other trials, at 5-year follow-up in our study, patient- Kufner et al.
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